GB202105625D0 - Von willebrand factor (VWF) inhibitors - Google Patents

Von willebrand factor (VWF) inhibitors

Info

Publication number
GB202105625D0
GB202105625D0 GBGB2105625.4A GB202105625A GB202105625D0 GB 202105625 D0 GB202105625 D0 GB 202105625D0 GB 202105625 A GB202105625 A GB 202105625A GB 202105625 D0 GB202105625 D0 GB 202105625D0
Authority
GB
United Kingdom
Prior art keywords
vwf
inhibitors
von willebrand
willebrand factor
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2105625.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Ip2ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ip2ipo Innovations Ltd filed Critical Ip2ipo Innovations Ltd
Priority to GBGB2105625.4A priority Critical patent/GB202105625D0/en
Publication of GB202105625D0 publication Critical patent/GB202105625D0/en
Priority to MX2023012391A priority patent/MX2023012391A/es
Priority to AU2022262695A priority patent/AU2022262695A1/en
Priority to CA3214716A priority patent/CA3214716A1/en
Priority to IL307441A priority patent/IL307441A/en
Priority to BR112023021631A priority patent/BR112023021631A2/pt
Priority to CN202280030093.5A priority patent/CN117597367A/zh
Priority to US18/556,638 priority patent/US20240228660A1/en
Priority to JP2023565152A priority patent/JP2024514708A/ja
Priority to PCT/GB2022/050989 priority patent/WO2022223966A1/en
Priority to EP22720748.7A priority patent/EP4326778A1/en
Priority to KR1020237036079A priority patent/KR20240004332A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2105625.4A 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors Ceased GB202105625D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2105625.4A GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors
KR1020237036079A KR20240004332A (ko) 2021-04-20 2022-04-20 폰 빌레브란트 인자(vwf) 억제제
IL307441A IL307441A (en) 2021-04-20 2022-04-20 von Willebrand factor (VWF) inhibitors
AU2022262695A AU2022262695A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors
CA3214716A CA3214716A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors
MX2023012391A MX2023012391A (es) 2021-04-20 2022-04-20 Inhibidores del factor von willebrand (vwf).
BR112023021631A BR112023021631A2 (pt) 2021-04-20 2022-04-20 Inibidor, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, sequência de polinucleotídeo, cassete de expressão, vetor recombinante, célula hospedeira, métodos para preparar o anticorpo ou fragmento de ligação a antígeno e para diagnosticar ou prognosticar uma condição causada pela aglutinação mediada por plaqueta, kit para diagnosticar um indivíduo, e, uso
CN202280030093.5A CN117597367A (zh) 2021-04-20 2022-04-20 血管性血友病因子(vwf)抑制剂
US18/556,638 US20240228660A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors
JP2023565152A JP2024514708A (ja) 2021-04-20 2022-04-20 フォンウィルブランド因子（ｖｗｆ）阻害剤
PCT/GB2022/050989 WO2022223966A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors
EP22720748.7A EP4326778A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2105625.4A GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors

Publications (1)

Publication Number Publication Date
GB202105625D0 true GB202105625D0 (en) 2021-06-02

Family

ID=76377797

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2105625.4A Ceased GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors

Country Status (12)

Country Link
US (1) US20240228660A1 (https=)
EP (1) EP4326778A1 (https=)
JP (1) JP2024514708A (https=)
KR (1) KR20240004332A (https=)
CN (1) CN117597367A (https=)
AU (1) AU2022262695A1 (https=)
BR (1) BR112023021631A2 (https=)
CA (1) CA3214716A1 (https=)
GB (1) GB202105625D0 (https=)
IL (1) IL307441A (https=)
MX (1) MX2023012391A (https=)
WO (1) WO2022223966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202215432D0 (en) * 2022-10-19 2022-11-30 Ip2Ipo Innovations Ltd Von Willebrand factor (VWF) antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2543678A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis

Also Published As

Publication number Publication date
JP2024514708A (ja) 2024-04-02
US20240228660A1 (en) 2024-07-11
MX2023012391A (es) 2024-02-02
CN117597367A (zh) 2024-02-23
KR20240004332A (ko) 2024-01-11
IL307441A (en) 2023-12-01
EP4326778A1 (en) 2024-02-28
WO2022223966A1 (en) 2022-10-27
CA3214716A1 (en) 2022-10-27
AU2022262695A1 (en) 2023-10-05
BR112023021631A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
EP4010130A4 (en) MODULAR PACKAGING SORTING SYSTEM
EP3940038C0 (en) LUMINESCENT COMPONENT
JP1746373S (ja) 容器運搬具
EP4070629C0 (de) Wechselrichter mit kompakter bauform
SG11201708755WA (en) Truncated von willebrand factor polypeptides for treating hemophilia
JP1780423S (ja) 容器運搬具
IL307441A (en) von Willebrand factor (VWF) inhibitors
JP1716509S (ja) 断熱容器
SG10201912498YA (en) Mutated truncated von willebrand factor
EP3618256A4 (en) BRIDGE CIRCUIT FOR INVERTERS OR RECTIFIERS
EP4100121A4 (en) REGULATION OF THE VON WILLEBRAND FACTOR (VWF)
JP1759121S (ja) 断熱容器
EP4209344A4 (en) LAMINATED GLASS
JP1746372S (ja) 容器運搬具
JP1765892S (ja) 容器運搬具
JP1765994S (ja) 容器運搬具
EP4101857C0 (en) MODIFIED LUMINESCENT COMPONENT
EP4069324C0 (en) FLUID THROMBIN FIBRINOGEN PASTE
JP1716510S (ja) 断熱容器
JP1716508S (ja) 断熱容器
SG10201912360SA (en) Truncated von willebrand factor polypeptides for treating hemophilia
GB202215432D0 (en) Von Willebrand factor (VWF) antibody
HK40107045A (en) Von willebrand factor (vwf) inhibitors
DE112020002376A5 (de) Multi-chip trägerstruktur
JP1716507S (ja) 断熱容器

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)